arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Protara Therapeutics, Inc.

TARA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.94
Today
as of Sep 4, 16:55 ET
Last 30 days -2.48% Jul 27 → Sep 04
$3.79 $3.88 $3.96 $4.05 $4.14 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$3.93
High
$3.96
Low
$3.89
Volume
$203,006
Avg Vol
$767,317
Mkt Cap
$230M
P/E (TTM)
—
Beta
—
52w High
$7.82
52w Low
$3.02
Div Yield
—
Shares Out
$59M

Recent Press Releases & News last 60 days · 3 items

Aug 11 · 12:11 Associated Press
Protara Therapeutics: Q2 Earnings Snapshot
Aug 11 · 12:00 PR GlobeNewswire
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Jul 21 · 16:00 Zacks
What Makes Protara Therapeutics (TARA) a New Buy Stock

Overview

52-week range
$3.02
$7.82
19% of range
Avg surprise (last 3)
+23.6%
Avg reaction (last 2)
+0.8%
100% positive
Latest IV / EM
349%
EM ±54.6% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.00$-0.82$-0.65$-0.47$-0.29 Actual $-0.80Actual $-1.00Actual $-0.87Actual $-0.97Actual $-0.45Actual $-0.50Actual $-0.29Est $-0.47Actual $-0.35Est $-0.43Actual $-0.31Actual $-0.31Est $-0.36Actual $-0.36 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-22M$-19M$-17M$-14M$-12M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.36 — — — — financials
Wed May 13, 2026Mar/2026 $-0.31 $-0.36 +13.9% -6.9% +1.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.31 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.35 $-0.43 +18.6% — — earnings
Thu May 8, 2025Mar/2025 $-0.29 $-0.47 +38.3% — +0.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.50 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.45 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.97 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.87 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.00 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.80 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-23M$-20M—$-15M$-17M$-14M—$-12M
Net income$-22M$-18M—$-13M$-15M$-12M—$-11M
EPS (diluted)$-0.36$-0.31—$-0.31$-0.35$-0.29—$-0.50

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$17M$15M$50M$13M$31M$91M$163M$52M
Inventory————————
Total current assets$146M$140M$160M$136M$125M$127M$172M$85M
Total assets$176M$192M$209M$145M$157M$169M$181M$94M
Long-term debt————————
Total liabilities$15M$11M$13M$12M$13M$10M$14M$12M
Total equity$161M$181M$196M$132M$144M$158M$167M$82M

Implied volatility — last 90 days

148%786%1425%2063%2701% Jun 07 — IV 286% · EM ±39.7%Jun 08 — IV 478% · EM ±63.1%Jun 09 — IV 412% · EM ±51.6%Jun 10 — IV 484% · EM ±57.1%Jun 11 — IV 806% · EM ±89.0%Jun 12 — IV 639% · EM ±65.4%Jun 15 — IV 754% · EM ±54.6%Jun 16 — IV 899% · EM ±53.1%Jun 17 — IV 1088% · EM ±45.5%Jun 19 — IV 210% · EM ±46.5%Jun 22 — IV 262% · EM ±54.7%Jun 23 — IV 257% · EM ±52.5%Jun 24 — IV 489% · EM ±98.0%Jun 25 — IV 306% · EM ±60.0%Jun 29 — IV 278% · EM ±49.3%Jun 30 — IV 342% · EM ±58.9%Jul 01 — IV 341% · EM ±56.9%Jul 02 — IV 259% · EM ±41.9%Jul 03 — IV 268% · EM ±41.9%Jul 06 — IV 425% · EM ±58.8%Jul 07 — IV 160% · EM ±21.1%Jul 10 — IV 251% · EM ±27.8%Jul 13 — IV 358% · EM ±29.9%Jul 14 — IV 507% · EM ±36.7%Jul 15 — IV 555% · EM ±32.8%Jul 16 — IV 779% · EM ±32.5%Jul 20 — IV 198% · EM ±46.7%Jul 21 — IV 210% · EM ±48.9%Jul 22 — IV 171% · EM ±39.2%Jul 23 — IV 149% · EM ±33.4%Jul 24 — IV 253% · EM ±56.0%Jul 27 — IV 267% · EM ±55.7%Jul 28 — IV 230% · EM ±47.0%Jul 29 — IV 223% · EM ±44.6%Jul 30 — IV 310% · EM ±60.8%Jul 31 — IV 293% · EM ±56.1%Aug 03 — IV 249% · EM ±44.1%Aug 04 — IV 301% · EM ±51.9%Aug 05 — IV 269% · EM ±45.0%Aug 06 — IV 264% · EM ±42.7%Aug 07 — IV 327% · EM ±51.1%Aug 10 — IV 342% · EM ±47.3%Aug 11 — IV 300% · EM ±39.6%Aug 12 — IV 441% · EM ±55.3%Aug 13 — IV 279% · EM ±33.0%Aug 14 — IV 490% · EM ±54.2%Aug 17 — IV 466% · EM ±38.9%Aug 18 — IV 747% · EM ±54.0%Aug 19 — IV 1133% · EM ±66.9%Aug 20 — IV 2701% · EM ±112.8%Aug 24 — IV 297% · EM ±62.0%Aug 25 — IV 302% · EM ±61.7%Aug 26 — IV 383% · EM ±76.7%Aug 27 — IV 301% · EM ±58.9%Aug 28 — IV 294% · EM ±56.3%Aug 31 — IV 475% · EM ±84.2%Sep 01 — IV 350% · EM ±60.3%Sep 02 — IV 319% · EM ±53.3%Sep 03 — IV 350% · EM ±56.7%Sep 04 — IV 349% · EM ±54.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in